Newcastle Clinical Trials Unit

Graves PCD


Randomised controlled trial of plasma cell depletion for severe Graves’ disease.

  • Study stage: Recruiting
  • Sponsor: The Newcastle upon Tyne Hospitals NHS Foundation Trust
  • Funder: MRC
  • Therapeutic area: Metabolic and Endocrine
  • Type of study: CTIMP

Aim: To determine if daratumumab modulates the humoral immune response in Graves’ disease patients

Primary Outcome:

Change in serum TRAb antibodies from baseline to 12 weeks compared to change in placebo group

  • Population: Adult
  • Phase: IIa
  • Design: Adaptive
  • Setting: Secondary care
  • Planned Sample Size: 30